TransCode Therapeutics Receives Nasdaq Deficiency Notice Regarding Stockholders' Equity Requirement

On May 19, 2026, TransCode Therapeutics, Inc. received a deficiency letter from the Nasdaq Stock Market notifying the company that it is no longer in compliance with the minimum stockholders' equity requirement for continued listing on the Nasdaq Capital Market. Under Nasdaq Listing Rule 5550(b)(1), listed companies must maintain a minimum stockholders' equity of $2,500,000. TransCode's Quarterly Report for the period ended March 31, 2026, reported stockholders' equity of $1,251,427, falling short of the requirement. The notification does not result in an immediate delisting. The company has 45 calendar days, until July 3, 2026, to submit a compliance plan to Nasdaq. If accepted, Nasdaq may grant an extension of up to 180 days to regain compliance. Potential strategies to address the deficiency include equity financings or improved operational results. If the plan is rejected or compliance is not achieved within the extension period, the company faces potential delisting, though it retains the right to appeal to a Nasdaq Hearings Panel.